A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas
Latest Information Update: 09 Mar 2026
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Trabectedin (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
Most Recent Events
- 09 Mar 2026 New trial record